Genome&Company Announces Three Research Achievements at AACR 2022, the American Association for Cancer Research

New Immune Checkpoint Inhibitor Target 'GENA-104A16'
ADC Candidate 'GENA-111-AF'
Three New Immune Checkpoint Targets Including 'GICP-105'

[Asia Economy Reporter Lee Gwan-joo] Genome & Company announced on the 10th that three research presentation abstracts to be presented at the American Association for Cancer Research (AACR) next month have been released on the official AACR website.

Genome & Company will present research on new immune-oncology antibody candidates, antibody-drug conjugate (ADC) candidates, and new immune-oncology targets. The accepted presentation topics are ▲Preclinical research results of the immune-oncology drug ‘GENA-104A16 (code name)’ that inhibits the new immune-oncology target ‘CNTN-4’ ▲Research results of the ADC candidate ‘GENA-111-AF’ being co-developed with Debiopharm ▲New immune-oncology target ‘GICP-105’.

‘CNTN-4’ is a new immune-oncology target discovered independently through Genome & Company’s drug development platform (GNOCLE™). Genome & Company will introduce for the first time the preclinical research results of the optimized clinical candidate ‘GENA-104A16’ of GENA-104 this year. GENA-104 aims to obtain clinical trial approval (IND) in the first half of 2023.

Research results of the ADC candidate, which began joint research and development with the global pharmaceutical company Debiopharm in February last year, will also be presented. Based on Genome & Company’s drug development platform GNOCLE™, the two companies have discovered multiple antibodies targeting new tumors and have been jointly developing ADC candidates by applying Debiopharm’s Multilink™ technology, which precisely delivers antibodies to antigens.

Cha Mi-young, head of the new drug research institute, said, “It is encouraging to be able to present meaningful joint research results, including GENA-104, which was first revealed at last year’s AACR,” and added, “As interest in new target immune-oncology drugs continues to grow, we plan to accelerate discussions on global partnerships.” CEO Bae Ji-soo emphasized, “We will leap forward as a global leader in immune-oncology drugs through research and development achievements not only in the microbiome but also in the new target immune-oncology drug field.”

The American Association for Cancer Research (AACR) is a prestigious annual conference attended by over 120 countries worldwide, sharing basic and clinical research on cancer. This year, it will be held in New Orleans, USA, from April 8 to 13, with online posts released on April 8.

This content was produced with the assistance of AI translation services.